A Study to Evaluate the Safety and Efficacy of AV-1 Against Dengue Virus 3 (DENV-3) Infection
Phase 2
Recruiting
- Conditions
- DENV-3 Controlled Human Infection Model
- Interventions
- Drug: AV-1 100 mgDrug: AV-1 300 mgDrug: AV-1 900 mgDrug: Placebo
- First Posted Date
- 2025-01-29
- Last Posted Date
- 2025-04-25
- Lead Sponsor
- AbViro LLC
- Target Recruit Count
- 84
- Registration Number
- NCT06799741
- Locations
- 🇺🇸
Center for Immunization Research Inpatient Unit, Baltimore, Maryland, United States
🇺🇸Center for Immunization Research (CIR) JHBSPH, Baltimore, Maryland, United States
🇺🇸UVM Larner College of Medicine Department of MMG, Burlington, Vermont, United States
A Study to Determine the Safety of AV-1, an Antibody Being Developed for Treatment of Dengue, in Healthy Volunteers
- First Posted Date
- 2020-02-18
- Last Posted Date
- 2022-10-31
- Lead Sponsor
- AbViro LLC
- Target Recruit Count
- 42
- Registration Number
- NCT04273217
- Locations
- 🇺🇸
PPD Austin Clinic, 7551 Metro Center Drive, Suite 200, Austin, Texas, United States
© Copyright 2025. All Rights Reserved by MedPath